Overall haemostatic potential can be used for estimation of thrombin-activatable fibrinolysis inhibitor-dependent fibrinolysis in vivo and for possible follow-up of recombinant factor VIIa treatment in patients with inhibitors to factor VIII

This publication has 11 references indexed in Scilit:

• Total thrombin‐activatable fibrinolysis inhibitor (TAFI) antigen and pro‐TAFI in patients with haemophilia A
  Haemophilia, 2001
• A Simple and Rapid Laboratory Method for Determination of Haemostasis Potential in Plasma
  Thrombosis Research, 2001
• High‐dose factor VIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia‐like conditions in a cell‐based model system
  British Journal of Haematology, 2001
• Plasma TAFI Antigen Variations in Healthy Subjects
  Thrombosis and Haemostasis, 2000
• The Effect of DDAVP Infusion on Thrombin Generation in Platelet-rich Plasma of von Willebrand Type 1 and in Mild Haemophilia A Patients
  Thrombosis and Haemostasis, 2000
• Treatment of Patients with Factor VIII and Factor IX Inhibitors with Special Focus on the Use of Recombinant Factor VIIa
  Thrombosis and Haemostasis, 1999
• A Study of the Mechanism of Inhibition of Fibrinolysis by Activated Thrombin-activable Fibrinolysis Inhibitor
  Journal of Biological Chemistry, 1998
• Plasma TAFI Levels Influence the Clot Lysis Time in Healthy Individuals in the Presence of an Intact Intrinsic Pathway of Coagulation
  Thrombosis and Haemostasis, 1998
• Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis.
  Journal of Clinical Investigation, 1997
• TAFI, or Plasma Procarboxypeptidase B, Couples the Coagulation and Fibrinolytic Cascades through the Thrombin-Thrombomodulin Complex
  Published by Elsevier ,1996